Ozempic's Impact On Brain Chemistry May Influence Depression Risk: Study
Researchers have discovered a possible connection between popular weight loss medications, such as Ozempic and Wegovy, and brain changes that may lead to depression. These medications, known as GLP-1 drugs, mimic a natural hormone that regulates blood sugar and appetite. However, studies suggest they may also affect parts of the brain related to dopamine, a chemical linked to feelings of pleasure and reward.
According to the research that was published in the journal Current Neuropharmacology, GLP-1 drugs may disrupt dopamine levels, potentially leading to depression and suicidal thoughts in individuals with low dopamine function. While these medications show promise in treating obesity and diabetes, further investigation is needed to understand their potential impact on mental health.
As per a news release, the study, led by researchers across the United States, Brazil, Iran, and Israel, demonstrates that while GLP1 agonists benefit individuals with hyperdopaminergia (excess dopamine activity), they may have harmful effects on individuals with hypodopaminergia (low dopamine function). The authors found genetic associations between GLP1 receptor agonists and genes such as DRD3, BDNF, and CREB1, which are implicated in mood regulation and reward pathways. Their findings suggest that chronic use of these drugs could dysregulate dopamine signalling, potentially leading to depressive symptoms, mood disturbances, and SI.
Cautionary Voices from Experts
While the idea of GLP-1 agonism induction of depression and SI is controversial with both negative and positive reporting, based on the evidence presented in this article by Alireza Sharafshah, a PhD candidate from the Cellular and Molecular Research Centre, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran, the authors caution against promoting chronic stimulation via GLP-1 agonists.
"This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP-1 receptor agonists," said senior author Dr Kenneth Blum, research professor at Western University Health Sciences and Ariel University. "We urge the clinical prescribing community to proceed with caution to avoid another tragic wave of 'people dying to lose weight'."
Dr Mark S Gold, an addiction psychiatry pioneer and co-author, emphasised, "The paper provides critical evidence for re-evaluating the widespread use of GLP1 receptor agonists. The FDA and other regulatory agencies should carefully consider our findings when it comes to labelling and monitoring these drugs."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
15 hours ago
- First Post
40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives
The weight loss drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity read more There have been at least 40 cases of unexpected pregnancies associated with weight loss drugs. Pixabay British health authorities have issued a warning to women using weight-loss medications such as Ozempic, Wegovy and Mounjaro, urging them to use effective contraception after dozens of pregnancy reports linked to the drugs. The Medicines and Healthcare products Regulatory Agency (MHRA) on Friday (May 6) released its first public safety alert addressing the use of weight-loss drugs and contraception. The agency said it had received 40 reports of pregnancies involving users of medications that include the active ingredients semaglutide or tirzepatide, The Guardian reported. STORY CONTINUES BELOW THIS AD Ozempic and Wegovy, which both contain semaglutide, mimic a gut hormone called GLP-1 that helps reduce appetite by slowing digestion and increasing insulin production. Mounjaro, which contains tirzepatide, also targets a second hormone involved in blood sugar and appetite control. Though often referred to as 'weight-loss injections,' not all of the drugs are formally authorised for weight loss. Drugs not advised during pregnancy or attempts to conceive The MHRA said the drugs should not be taken during pregnancy, while trying to conceive, or while breastfeeding due to a lack of safety data. In some cases, the agency recommends that women continue contraception for up to two months after stopping the medication before attempting pregnancy. Among the 40 reports, eight were associated with semaglutide and nine with liraglutide, which is found in the weight-loss drug Saxenda. Two cases were explicitly reported as unintended pregnancies. Dr. Channa Jayasena, a reproductive endocrinologist at Imperial College Healthcare NHS Trust, said the drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity. 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' he said. He also noted that the medications may interfere with the absorption of oral contraceptives due to delayed stomach emptying, although further research is needed. Officials stress responsible use Dr. Alison Cave, the MHRA's chief safety officer, warned that the medications should not be used as quick fixes for weight loss or for cosmetic purposes. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Cave said. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way.' The MHRA said it has published updated guidance to help patients use the medications safely but emphasized that the advice should not replace consultation with a healthcare provider. STORY CONTINUES BELOW THIS AD Dr. Jayasena added that while the risks of GLP-1 drugs in pregnancy are not fully known, similar weight-loss interventions like surgery have been associated with higher miscarriage rates. 'So women are advised to do all they can to prevent pregnancy while taking GLP-1 drugs,' he said.
NDTV
20 hours ago
- NDTV
Ozempic Side-Effect: Male Users Claim Shocking Change After Taking Weight Loss Drug
Men using Ozempic, a popular weight-loss injection, have reported an unexpected side effect - an increase in perceived penis size. Numerous users have taken to online forums and social media platforms to share their experiences, claiming that their private parts appear larger since starting the medication. While anecdotal, these claims have sparked lively conversations, with dozens of men attributing their enhanced confidence and physical changes to the drug. The phenomenon has yet to be formally studied, but it's generating buzz as a surprising potential perk of the weight-loss treatment. One person wrote on Reddit, "I recently measured myself down there and noticed I gained about one inch. Now I think people will say it was because of the fat loss. However, at the time I measured myself before (4 years ago), I was thinner. I also pressed during measurement before, and also this time. Has anyone else noticed this change in themselves?" Another Reddit user shared, "Yes. I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss." Some men attributed it to improved blood flow and reduced pubic fat due to weight loss. However, a Redditor suggested that the apparent size difference might result from varying external conditions, such as temperature or arousal levels, during before-and-after measurements rather than the drug itself. "I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter. Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that," he explained. Other Ozempic Side Effects This is not the only side effect linked to the weight loss drug. Recently, some users reported "Ozempic teeth," characterised by various dental problems, including dry mouth, bad breath, gum disease, and tooth decay. According to reports, the drug's appetite-suppressing effect reduces food intake, which in turn decreases salivary gland stimulation. Reduced saliva flow increases the risk of cavities and gum issues. Additionally, some users experience nausea or vomiting, which can expose teeth to stomach acid, further eroding enamel. According to the New York Post, a doctor previously warned about "Ozempic mouth". The condition is marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area. Other complications include "Ozempic face" and "Ozempic butt". "Ozempic face" refers to the prematurely aged look some patients develop after shedding pounds at record speed. "Ozempic butt" on the other hand, refers to the saggy rear end some users are complaining about.
Mint
a day ago
- Mint
Not Ozempic, in India THIS weigh-loss and diabetes drug from Eli Lilly sees sales jump 60% — what is it?
While rival Ozempic has made international headlines for its weightloss use, in India, sales of weight-loss and diabetes drug Mounjaro, manufactured by pharma giant Eli Lilly, has been the big winner. Largely due to first mover advantage, sales of Mounjaro jumped 60 per cent in May 2025, compared to the previous month, according to a Bloomberg report. Notably, May was the second full month that the tirzepatide injection drug has been available to patients in India, which has the third-highest number of obese people in the world, the report added. According to data from market analysis company Pharmarack Technologies, Eli Lilly sold $1.5 million or ₹ 12.6 crore worth of Mounjaro in India in May 2025. Further, sales of the the US drugmaker's 5 mg version have more than doubled to ₹ 7.5 crore, while revenue from the 2.5 mg version was ₹ 5.1 crore, the data showed. 'The patient number may have actually doubled in May from April. The demand is gradually rising and should continue. Newer patients are being introduced with the lower dose and upgraded to 5 mg injections after four weeks,' Sheetal Sapale, VP of Pharmarack told Bloomberg News. Eli Lilly's Mounjaro is a brand-name subcutaneous injection pen, chemically known as tirzepatide. It is a weekly injectable medication for obesity and type 2 diabetes. It has been approved for sale in India by the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels. According to a report by Healthline, it works by helping your body to produce more insulin when needed. It also reduces the amount of glucose, or sugar, produced by the liver, and slows down how quickly food is digested. This all helps to lower blood sugar levels and HbA1c. It increases how sensitive your body is to insulin and signals your pancreas to make more insulin after you eat. Mounjaro weekly injection is priced at ₹ 4,375 ($50.67) for a 5 mg vial and ₹ 3,500 ($40.54) for a 2.5 mg vial, its lowest doses, the company told new agency Reuters. Its highest dose is 15 mg. A patient in India may have to spend about ₹ 14,000 to ₹ 17,500 (around $200) a month when taking a weekly dose of 5 mg, subject to doctor's prescription. Biocon on June 3 recieved approval to produce Novo Nordisk's celebrated type-2 diabetes and anti-obesity drug Victoza in India. Victoza is the Norweigian pharma giant's daily dose option for Ozempic, which is administered weekly. 'It's difficult to guide on exactly when Ozempic is coming to what countries,' Camilla Sylvest, executive vice president at Novo Nordisk, said at a briefing in March 2025, addressing a question on the brand's potential India launch. While Ozempic itself has not been launched in India, its patent is quickly approaching patent expiry in January 2026, and India's top generics players such as Cipla, Dr Reddy's and Sun Pharma (besides Biocon) are rushing to develop versions of GLP-1 drugs. The main difference between Mounjaro and Ozempic lies in their active ingredients. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors, while Ozempic contains semaglutide, which only targets GLP-1 receptors. According to Goldman Sachs, the market for GLP-1 drugs is expected to reach $100 billion by 2030. In India too, the market is considered to be vast, as the country has around 10 crore people living with diabetes and obesity each, Eli Lilly had said earlier this year. (With inputs from Agencies)
